infecti
tropic
diseas
huge
effect
term
mortal
morbid
impos
heavi
econom
burden
affect
countri
diseas
predominantli
affect
world
poorest
peopl
current
avail
drug
inadequ
major
diseas
urgent
need
new
treatment
review
discuss
challeng
involv
develop
new
drug
treat
diseas
highlight
recent
progress
notabl
success
still
long
way
go
nfectiou
tropic
diseas
mainli
affect
lowand
middleincom
countri
lmic
symptom
includ
impair
cognit
physic
develop
children
box
complic
pregnanc
fever
nausea
diarrhoea
dehydr
anaemia
rash
lesion
deform
blind
organ
failur
haemorrhag
neurolog
problem
seizur
coma
mani
case
death
world
health
organ
estim
diseas
list
fig
tabl
respons
million
death
loss
million
disabilityadjust
life
year
dali
owe
illhealth
prematur
disabl
earli
death
infecti
tropic
diseas
includ
defin
neglect
tropic
diseas
ntd
addit
diseas
malaria
tuberculosi
hivaid
multidrugresist
gramneg
bacteri
infect
diarrhoea
varieti
pathogen
hepat
disproportion
affect
tropic
countri
common
tropic
diseas
group
caus
agent
includ
virus
ebola
hivaid
lassa
fever
marburg
viru
diseas
rift
valley
fever
yellow
fever
zika
diseas
ntd
chikungunya
dengu
fever
rabi
ii
bacteria
bubon
plagu
shigellosi
tuberculosi
typhoid
fever
typhu
diseas
caus
drugresist
gramneg
bacteria
ntd
buruli
ulcer
leprosi
mycetoma
trachoma
yaw
iii
protozoa
cryptosporidiosi
malaria
ntd
chaga
diseas
human
african
trypanosomiasi
hat
leishmanias
viscer
cutan
postkalaazar
dermal
mucocutan
iv
fungi
cryptococcosi
ntd
mycetoma
v
helminth
metazoan
worm
ntd
cysticercosi
dracunculiasi
guinea
worm
echinococcosi
foodbourn
trematodias
clonorchiasi
opisthorchiasi
fasciolosi
lymphat
filariasi
onchocerciasi
schistosomiasi
soiltransmit
helminthias
ascariasi
hookworm
trichuriasi
strongyloidiasi
coinfect
diseas
commonplac
exacerb
symptom
complic
treatment
box
infecti
tropic
diseas
inflict
heavi
econom
burden
cost
lmic
economi
billion
dollar
everi
year
exampl
annual
global
cost
dengu
estim
us
billion
studi
carri
philippin
indic
schistosomiasi
result
loss
averag
work
day
per
infect
person
per
year
mani
diseas
current
treatment
unsatisfactori
treatment
option
avail
urgent
need
new
safe
lowcost
efficaci
treatment
tackl
diseas
effect
requir
integr
multisector
approach
link
chemotherapi
prevent
initi
improv
water
suppli
sanit
hygien
vaccin
vector
control
variou
government
nongovernment
organ
chariti
foundat
productdevelop
partnership
academ
group
pharmaceut
compani
support
drug
discoveri
tropic
diseas
breakdown
fund
summar
gfinder
ifpma
report
twothird
total
fund
research
develop
neglect
diseas
spent
hivaid
malaria
tuberculosi
overal
research
develop
fund
markedli
increas
last
decad
gain
distribut
evenli
across
diseas
greater
effort
resourc
fund
urgent
need
meet
consider
unmet
medic
need
review
consid
specif
challeng
associ
drug
discoveri
tropic
diseas
examin
recent
success
figur
show
pathway
typic
smallmolecul
drugdiscoveri
programm
infecti
diseas
mani
tropic
infecti
diseas
littl
preced
develop
smallmolecul
drug
exacerb
insuffici
understand
pathogen
biolog
result
often
relev
cellular
predict
anim
model
human
diseas
also
frequent
littl
data
clinic
activ
molecul
help
research
defin
profil
new
drug
term
activ
preclin
assay
anim
model
pharmacokinet
key
issu
face
research
seek
discov
new
drug
treat
tropic
diseas
summar
fig
consid
biolog
challeng
wellvalid
molecular
drug
target
tropic
diseas
part
owe
lack
understand
detail
biolog
mani
pathogen
exampl
function
mani
protein
unknown
infer
organ
therefor
key
challeng
select
suitabl
molecular
target
limit
risk
subsequ
failur
criteria
use
help
select
appropri
target
includ
essenti
druggabl
assay
opportun
select
host
orthologu
even
target
compli
criteria
inhibitor
frequent
fail
demonstr
cellbas
activ
owe
poor
permeabl
inabl
compet
high
substrat
concentr
cell
compound
inhibit
target
suffici
kill
pathogen
defici
genet
tool
mani
diseaserelev
organ
key
reason
littl
essenti
data
avail
howev
new
techno
logi
emerg
includ
offer
prospect
markedli
increas
number
valid
target
avail
near
futur
largescal
cellbas
phenotyp
screen
current
popular
approach
identifi
new
chemic
start
point
requir
prior
knowledg
molecular
target
develop
assay
suffici
throughput
allow
screen
compound
librari
maintain
relev
diseas
pathophysiolog
challeng
help
reduc
attrit
use
vivo
model
ultim
clinic
trial
assay
increas
relev
usual
becom
complex
requir
resourc
term
specialist
equip
well
staff
develop
run
assay
challeng
may
includ
lack
robust
vitro
cultur
system
exampl
cryptosporidium
inher
safeti
challeng
handl
diseasecaus
agent
bulk
lack
standard
differ
laboratori
work
organ
use
laboratori
strain
cell
line
rather
recent
clinic
isol
primari
cell
exist
anim
model
tropic
diseas
infect
often
poorli
repres
human
diseas
exampl
onchocerciasi
river
blind
caus
worm
onchocerca
volvulu
infect
primat
consequ
relat
differ
worm
speci
use
mice
cattl
model
plasmodium
falciparum
pathogen
caus
sever
form
human
malaria
infect
rodent
normal
howev
scid
mous
model
develop
infect
p
falciparum
work
also
ongo
develop
mous
model
human
malaria
caus
plasmodium
vivax
mous
model
tuberculosi
replic
human
diseas
well
form
granuloma
typic
human
diseas
encouragingli
progress
made
develop
anim
model
close
replic
human
patholog
recent
human
clinic
trial
azol
inhibit
enzym
treatment
chaga
diseas
success
mous
model
develop
distinguish
benznidazol
known
clinic
efficaci
azol
posaconazol
better
differenti
preclin
stage
improv
success
rate
clinic
trial
quiescenc
dormanc
dormant
infect
complic
aetiolog
diseas
malaria
p
vivax
plasmodium
oval
remain
dormant
hypnozoit
hepatocyt
human
host
week
year
potenti
caus
relaps
latent
tuberculosi
clinic
symptom
absent
risk
progress
clinic
diseas
estim
affect
third
global
popul
dormanc
recent
identifi
trypanosoma
cruzi
quiescent
dormant
pathogen
reduc
metabol
compar
activ
divid
pathogen
may
therefor
less
suscept
drug
develop
assay
form
pathogen
problemat
effect
treat
elimin
diseas
new
drug
need
effect
tackl
reservoir
dormant
quiescent
infect
chemistri
essenti
compound
use
treatment
dose
appropri
usual
oral
reach
part
bodi
pathogen
locat
physicochem
properti
molecul
molecular
weight
solubl
lipophil
charg
number
hydrogen
bond
donor
acceptor
fundament
achiev
case
penetr
pathogen
problemat
exampl
gramneg
bacteria
surround
outer
membran
drug
molecul
penetr
protein
form
channel
membran
call
porin
tend
select
hydrophil
molecul
drug
travers
cell
membran
lipid
bilay
requir
compound
box
infant
children
mani
infecti
tropic
diseas
disproportion
affect
infant
children
case
malaria
major
death
occur
children
age
five
immunena
diarrhoea
major
problem
among
children
caus
hundr
thousand
death
per
year
global
enter
multicentr
studi
gem
casecontrol
studi
conduct
seven
site
africa
south
asia
comprehens
studi
childhood
diarrhoea
date
common
pathogen
found
studi
shigella
spp
rotaviru
adenoviru
heatstabl
enterotoxinproduc
escherichia
coli
cryptosporidium
spp
campylobact
spp
case
mix
infect
issu
tropic
diseas
cryptosporidiosi
schistosomiasi
soiltransmit
helminth
associ
malnutrit
growth
stunt
impair
cognit
develop
children
addit
drugdevelop
pathway
infant
children
complic
pharmacokinet
much
difficult
predict
infant
children
addit
safeti
test
requir
make
clinic
trial
challeng
furthermor
ethic
regul
clinic
trial
children
complex
review
research
degre
lipophil
therefor
penetr
cytoplasm
compound
requir
defin
chemic
properti
like
polar
charg
typic
drug
penetr
cytoplasm
drug
risk
pump
bacteria
efflux
transport
pathogen
cruzi
chlamydia
trachomati
mycobacterium
tuberculosi
virus
spend
major
life
cycl
insid
human
host
cell
imped
drug
access
pathogen
local
extrem
intracellular
environ
acid
organel
exampl
leishmania
spp
salmonella
spp
necrot
granuloma
exampl
tuberculosi
latter
case
major
challeng
design
drug
penetr
nonvascular
lipidrich
caseum
access
pathogen
infect
local
site
protect
bloodtissu
barrier
central
nervou
system
exampl
hat
cryptococcu
neoforman
taenia
solium
encephalitisor
meningitiscaus
virus
bacteria
eye
exampl
c
trachomati
reach
site
drug
need
pass
endotheli
cell
without
pump
back
blood
pglycoprotein
natur
diseas
mean
cost
treatment
must
low
malaria
aim
produc
treatment
cost
less
us
impli
short
cheap
chemic
synthesi
preclud
complex
formul
counter
issu
poor
solubl
owe
lack
temperaturecontrol
suppli
chain
mani
region
compound
stabl
long
period
time
high
temperatur
high
humid
requir
final
patient
complianc
also
challeng
often
compound
minim
medic
support
consequ
essenti
minim
number
dose
complex
dose
regimen
exampl
mmv
aim
singledos
treatment
bloodstream
malaria
resist
drug
resist
consider
problem
treatment
infecti
diseas
particular
viral
bacteri
apicomplexan
infect
poor
manag
treatment
acceler
occurr
resist
public
current
exampl
antibacteri
drug
resist
human
antibiot
sometim
taken
requir
given
subtherapeut
dose
potenti
increas
proport
resist
bacteria
within
popul
problem
aggrav
larg
amount
antibiot
environ
owe
indiscrimin
use
agricultur
aquacultur
combin
therapi
adopt
mani
diseas
attempt
slow
develop
drug
resist
particularli
success
treatment
hivaid
resist
rate
singl
therapi
except
high
combin
treatment
also
prove
effect
tuberculosi
malaria
worryingli
case
malaria
resist
artemisinin
combin
therapi
princip
form
treatment
develop
southeast
asia
therefor
need
drug
novel
mode
action
deliv
new
combin
therapi
clinic
resist
compon
despit
challeng
progress
gradual
made
exampl
highlight
although
comprehens
list
success
due
coordin
substanti
invest
research
along
concert
effort
understand
tpp
drugdiscoveri
pathway
million
case
year
human
econom
cost
malaria
extrem
high
africa
bear
disproportion
high
share
burden
death
year
multipl
new
type
antimalari
drug
need
overcom
resist
give
singledos
treatment
prevent
relaps
p
vivax
infect
block
transmiss
act
chemoprev
malaria
drugdiscoveri
portfolio
markedli
improv
past
decad
start
point
major
compound
current
develop
identifi
phenotyp
screen
collabor
mmv
mani
case
target
deconvolut
subsequ
led
identif
molecular
target
number
novel
compound
clinic
trial
support
collabor
mmv
fig
follow
deriv
phenotyp
screen
phase
ii
trial
spiroindolon
imidazolopiperazin
combin
trial
lumefantrin
synthet
trioxolan
artefenomel
combin
ferroquin
mode
action
determin
p
falciparum
pf
wherea
mode
action
remain
uncertain
link
cyclic
amin
resist
locu
pfcarl
probabl
act
format
carbon
radic
wherea
ferroquin
act
prevent
haem
detoxif
phase
trial
dihydroisoquinolin
anoth
inhibitor
activ
translat
elong
factor
two
compound
deriv
targetbas
project
also
clinic
trial
dihydroorot
dehydrogenas
inhibitor
phase
ii
trial
dihydrofol
reductas
inhibitor
phase
trial
envisag
increas
targetbas
drug
discoveri
modeofact
studi
reveal
chemic
valid
target
mani
recent
identifi
phenotyp
hit
systemat
effort
tri
identifi
mode
action
phenotyp
hit
new
type
phenotyp
screen
develop
target
lifecycl
stage
addit
asexu
blood
stage
clinic
develop
malaria
acceler
thank
develop
human
challeng
model
healthi
volunt
infect
treatabl
malaria
obtain
earli
indic
drug
efficaci
cryptosporidiosi
major
caus
diarrhoea
children
tropic
countri
box
nitazoxanid
current
treatment
diseas
variabl
efficaci
immunocompet
patient
effect
immunocomprom
patient
urgent
need
new
drug
treat
children
month
age
especi
malnourish
immunocomprom
suffer
chronic
diarrhoea
recent
advanc
cryptosporidiosi
discoveri
pipelin
seri
bump
kinas
inhibitor
cryptosporidium
parvum
calciumdepend
kinas
develop
exampl
promisingli
recent
advanc
c
parvum
highcont
imag
infect
assay
human
intestin
epitheli
cell
made
phenotyp
screen
mediumand
larges
compound
librari
possibl
screen
compound
activ
malaria
led
identif
preclin
candid
inhibitor
cryptosporidium
phosphatidylinositol
clofazimin
approv
drug
treatment
leprosi
identifi
screen
bioactiv
compound
enter
clinic
trial
cryptosporidiosi
area
recent
review
detail
mortal
rate
hat
also
known
sleep
sick
decreas
substanti
recent
year
howev
still
consider
diseas
burden
central
africa
advent
nifurtimoxeflornithin
nect
combin
therapi
mark
import
step
treatment
stage
two
brucei
gambiens
hat
reduc
durat
treatment
well
decreas
advers
effect
nevertheless
treatment
still
problemat
two
subspeci
caus
diseas
brucei
gambiens
brucei
rhodesiens
two
stage
acut
central
nervou
system
requir
differ
drug
requir
stage
patient
treatment
also
limit
uptak
involv
pain
technic
challeng
lumbar
punctur
ongo
develop
two
new
drug
potenti
transform
clinic
manag
hat
first
drug
fexinidazol
nitroaromat
compound
develop
broadspectrum
antibiot
recent
found
suitabl
profil
clinic
develop
hat
drug
neglect
diseas
initi
dndi
complet
phase
iii
clinic
trial
report
noninferior
nect
stage
diseas
tenday
oral
treatment
second
oxaborol
compound
acoziborol
current
undergo
pivot
phase
iiiii
trial
potenti
provid
singledos
oral
treatment
form
hat
less
progress
made
leishmaniasi
chaga
diseas
current
treatment
particularli
liposom
amphotericinb
given
intraven
togeth
measur
vector
control
effect
surveil
led
progress
toward
elimin
control
viscer
leishmaniasi
vl
indian
subcontin
howev
current
drug
less
effect
unsuit
area
world
new
oral
drug
urgent
need
treat
vl
region
provid
improv
treatment
option
indian
subcontin
furthermor
hivvl
coinfect
also
current
poorli
treat
sever
potenti
oral
treatment
identifi
phenotyp
screen
preclin
develop
includ
oxaborol
nitroimidazol
discoveri
pankinetoplastid
proteasom
inhibitor
fig
offer
potenti
develop
new
drug
leishmaniasi
chaga
diseas
hat
major
preclin
work
leishmaniasi
focus
vl
deadli
form
diseas
rather
cutan
leishmaniasi
cl
new
oral
therapi
cl
urgent
need
well
research
chaga
diseas
suffer
setback
recent
consequ
clinic
failur
inhibitor
posaconazol
fosravuconazol
current
treatment
develop
challeng
diseas
virus
hiv
hepat
c
viru
hcv
dengu
rabi
larg
global
impact
fig
result
million
death
effect
treatment
hiv
hcv
develop
virus
includ
flavivirus
arenavirus
coronavirus
filovirus
still
pose
consider
threat
tropic
countri
other
pose
particular
risk
global
pandem
exemplifi
recent
outbreak
zika
chikungunya
dengu
ebola
middl
east
respiratori
syndrom
mer
sinc
futur
epidem
almost
inevit
could
trigger
member
famili
drugdiscoveri
effort
rightli
focu
broadact
antivir
diseas
receiv
rel
littl
attent
term
smallmolecul
drug
discoveri
howev
targetbas
cellbas
hit
discoveri
approach
yield
new
compound
interest
date
none
develop
similar
degre
hcv
hiv
drug
advanc
compound
favipiravir
remdesivir
galidesivir
target
viral
polymeras
fig
favipiravir
test
human
ebola
viru
epidem
although
condit
complic
studi
conclud
investig
warrant
shown
activ
rhesu
monkey
model
ebola
also
use
human
ebola
outbreak
current
undergo
phase
ii
clinic
trial
west
africa
favipiravir
consid
use
ebola
viru
outbreak
democrat
republ
congo
demonstr
complet
protect
marburg
viru
nonhuman
primat
ebola
rodent
model
administ
within
h
infect
compound
also
show
broad
activ
virus
includ
arenavirus
flavivirus
current
clinic
develop
inhibitor
target
viral
proteas
far
advanc
except
hiv
hcv
howev
also
show
promis
broadspectrum
antivir
potenti
target
host
pathway
also
explor
although
new
smallmolecul
antivir
discov
urgent
need
translat
treatment
clinic
alongsid
ongo
vaccin
develop
tuberculosi
continu
major
problem
across
world
malaria
combin
treatment
use
tuberculosi
combat
resist
circumv
issu
tuberculosi
resid
multipl
environ
metabol
state
need
combin
therapi
complic
progress
new
compound
clinic
trial
http
wwwtballianceorgportfolio
recent
two
new
drug
bedaquilin
delamanid
condit
approv
treatment
specif
level
drugresist
tuberculosi
box
coinfect
associ
high
preval
extens
geograph
overlap
diseas
person
alreadi
infect
one
pathogen
may
case
increas
risk
infect
anoth
pathogen
issu
around
coinfect
coinfect
frequent
acceler
diseas
progress
outcom
one
diseas
enhanc
effect
anoth
exampl
malaria
infect
increas
viral
load
hivinfect
patient
also
make
easier
person
pass
hiv
viru
hivtuberculosi
coinfect
particularli
problemat
hiv
weaken
immun
system
allow
latent
tuberculosi
becom
activ
progress
rapidli
turn
tuberculosi
also
acceler
progress
hiv
infect
coinfect
result
complic
pregnanc
impair
growth
develop
children
exampl
coinfect
malaria
hookworm
lead
sever
deplet
haemoglobin
result
sever
anaemia
coinfect
complic
treatment
due
drugdrug
interact
affect
efficaci
give
rise
cumul
drug
toxic
produc
advers
side
effect
particular
problem
hivtuberculosi
coinfect
rifampicin
commonli
use
treat
tuberculosi
caus
induct
cytochrom
latter
metabol
commonli
use
antihiv
drug
mean
care
select
treatment
requir
coinfect
affect
diseas
treat
exampl
ivermectin
treatment
onchocerciasi
may
induc
sever
advers
reaction
peopl
sever
loa
loa
infect
review
research
basi
phase
iib
trial
current
undergo
phase
iii
studi
bedaquilin
target
atp
synthas
activ
latent
form
bacterium
delamanid
nitro
heterocycl
precis
mode
action
determin
probabl
prodrug
requir
activ
insid
bacterium
implic
inhibit
mycol
acid
biosynthesi
critic
structur
cell
wall
tuberculosi
number
compound
current
develop
treatment
tuberculosi
target
protein
synthesi
respiratori
chain
cell
envelop
http
wwwtballianceorgportfolio
http
wwwnewtbdrugsorgpipelineclin
sever
differ
step
protein
synthesi
studi
linezolid
demonstr
activ
drugresist
tuberculosi
mark
effect
patient
extens
drugresist
tuberculosi
member
oxazolidinon
class
molecul
target
ribosom
subunit
howev
advers
effect
associ
extend
treatment
period
linezolid
requir
multidrugresist
tuberculosi
link
mitochrondri
toxic
oxazolidinon
sutezolid
delpazolid
undergo
clinic
trial
avoid
mitochondri
toxic
allow
develop
oxazolidinon
analogu
higher
toler
oxaborol
inhibitor
leucyltrna
synthetas
enzym
involv
protein
synthesi
progress
clinic
trial
form
coval
adduct
acceptor
nucleotid
trna
boron
bind
group
complex
form
edit
site
inactiv
enzym
enter
clinic
trial
target
respiratori
pathway
inhibit
cytochrom
bc
pathway
target
bedaquilin
although
act
differ
step
hit
multipl
point
pathway
appear
enhanc
kill
bacterium
target
cell
wall
biosynthesi
also
reinvestig
treatment
tuberculosi
carbapenem
appear
potenti
class
compound
protein
target
much
weaker
substrat
tuberculosi
sever
enzym
involv
cell
envelop
biosynthesi
promiscu
target
includ
former
involv
biosynthesi
arabinogalactan
polysaccharid
critic
cell
wall
biosynthesi
benzothiazon
found
coval
inhibitor
enzym
one
compound
preclin
develop
anoth
undergo
clinic
evalu
http
wwwnewtbdrugsorgpipelineclin
two
noncoval
inhibitor
also
undergo
clinic
evalu
phase
azaindol
requir
export
mycol
acid
precursor
essenti
cell
wall
biosynthesi
compound
target
enzym
probabl
other
clinic
trial
sever
preclin
drugdiscoveri
programm
target
enoyl
reductas
inha
involv
biosynthesi
mycol
acid
inha
also
target
prodrug
isoniazid
nitroimidazol
pretomanid
activ
replic
nonrepl
mycobacteria
clinic
trial
like
delamanid
pretomanid
like
prodrug
number
compound
undergo
clinic
evalu
http
www
newtbdrugsorgpipelineclin
sever
fluoroquinolin
investig
combin
therapi
includ
moxifloxacin
levofloxacin
wherea
antibacteri
drug
resist
technic
neglect
tropic
diseas
impact
clearli
seen
lmic
high
level
drug
resist
recent
publish
prioriti
list
pathogen
prioriti
pathogen
enterobacteriacea
resist
carbapenem
third
gener
cephalosporin
acinetobact
baumannii
pseudomona
aeruginosa
carbapenemresist
new
drug
urgent
need
tackl
pathogen
drug
clinic
develop
address
addit
sever
bacteri
infect
shigellosi
typhoid
almost
exclus
affect
lmic
drug
resist
major
issu
worryingli
instanc
resist
bacteria
higher
fit
wildtyp
bacteria
treatment
reliant
exist
antibacteri
least
one
billion
peopl
probabl
estim
one
helminth
infect
nevertheless
new
antihelminth
drug
emerg
last
year
tribendimidin
show
promis
broadspectrum
activ
recent
clinic
trial
show
suitabl
altern
benzimidazol
praziquantel
variou
helminth
infect
beyond
develop
new
treatment
focus
repurpos
drug
mostli
involv
anthelminth
approv
veterinari
use
oxantel
pamoat
licens
veterinari
drug
sinc
shown
promis
efficaci
human
clinic
trial
trichuriasi
whipworm
one
difficulttotreat
soiltransmit
helminth
combin
albendazol
pyrantel
pamoat
recent
demonstr
high
clinic
efficaci
hookworm
infect
two
veterinari
drug
emodepsid
moxidectin
show
promis
activ
sever
human
helminth
current
undergo
clinic
trial
onchocerciasi
antimalari
compound
show
activ
schistosom
vitro
vivo
mefloquinepraziquantel
mefloquineartesunatepraziquantel
combin
test
clinic
trial
chronic
schistosoma
haematobium
infect
unfortun
advers
event
rate
high
increas
efficaci
compar
praziquantel
case
filari
worm
altern
strategi
target
wolbachia
endosymbiot
bacteria
result
slow
kill
worm
therebi
avoid
seriou
advers
event
exampl
four
week
treatment
doxycyclin
cure
peopl
suffer
onchocerciasi
major
aim
wolbachiadirect
therapi
find
shortercours
antibiot
sever
highthroughput
phenotyp
screen
carri
discov
new
chemic
entiti
act
helminth
infect
new
clinic
candid
report
date
fungal
infect
particularli
seriou
immunocomprom
patient
addit
common
fungal
infect
sever
found
predominantli
tropic
region
one
import
problem
mening
due
c
neoforman
estim
caus
death
per
year
among
peopl
infect
hiv
major
africa
poorli
treat
present
need
new
efficaci
drug
mycetoma
disfigur
infect
skin
soft
tissu
particularli
neglect
diseas
endem
tropic
subtrop
area
mycetoma
caus
bacteria
actinomycetoma
fungi
eumycetoma
fungal
mycetoma
requir
long
treatment
azol
drug
resist
diseas
recurr
side
effect
common
patient
often
develop
deform
requir
amput
dndi
current
run
phase
iiiii
trial
fosravuconazol
assess
whether
azol
effect
safer
current
use
azol
itraconazol
ketoconazol
comprehens
review
current
antifung
pipelin
publish
recent
current
treatment
use
tropic
diseas
suboptim
case
drug
avail
howev
recent
progress
drug
discoveri
human
african
trypanosomiasi
tuberculosi
malaria
show
headway
made
concert
effort
govern
chariti
foundat
productdevelop
partnership
academ
institut
pharmaceut
compani
still
long
way
go
even
diseas
area
high
attrit
rate
clinic
trial
issu
resist
mean
room
complac
multipl
new
agent
requir
diseas
area
allow
combin
therapi
progress
diseas
area
much
less
support
activ
other
